NYSE · BHC
Healthcare · Drug Manufacturers - Specialty & Generic
$5.67
Down-$0.25 (-4.22%)
Updated Sep 16, 2026, 1:06 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BHC closed at $5.67 after 20 trading sessions, down 18.18% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $5.90 | $5.91 | $5.635 | $5.67 | 1.61M |
| Sep 14, 2026 | $5.93 | $6.06 | $5.83 | $5.92 | 5.2M |
| Sep 11, 2026 | $6.124 | $6.125 | $5.835 | $5.86 | 2.41M |
| Sep 10, 2026 | $6.11 | $6.165 | $5.88 | $6.07 | 1.59M |
| Sep 9, 2026 | $6.38 | $6.47 | $6.14 | $6.16 | 1.43M |
| Sep 8, 2026 | $6.57 | $6.685 | $6.41 | $6.43 | 1.84M |
| Sep 4, 2026 | $6.71 | $6.72 | $6.52 | $6.56 | 1.65M |
| Sep 3, 2026 | $6.905 | $6.99 | $6.62 | $6.76 | 2.16M |
| Sep 2, 2026 | $6.56 | $6.87 | $6.535 | $6.83 | 7.72M |
| Sep 1, 2026 | $6.39 | $6.74 | $6.34 | $6.47 | 2.56M |
| Aug 31, 2026 | $6.36 | $6.375 | $6.135 | $6.37 | 2.51M |
| Aug 28, 2026 | $6.29 | $6.3591 | $6.23 | $6.32 | 1.39M |
| Aug 27, 2026 | $6.47 | $6.47 | $6.29 | $6.30 | 2.89M |
| Aug 26, 2026 | $6.69 | $6.82 | $6.50 | $6.51 | 2.14M |
| Aug 25, 2026 | $6.736 | $6.74 | $6.455 | $6.73 | 3.46M |
| Aug 24, 2026 | $6.44 | $6.71 | $6.43 | $6.68 | 2.71M |
| Aug 21, 2026 | $6.80 | $6.87 | $6.375 | $6.44 | 4.02M |
| Aug 20, 2026 | $6.82 | $6.91 | $6.67 | $6.81 | 1.93M |
| Aug 19, 2026 | $6.99 | $7.08 | $6.715 | $6.89 | 2.5M |
| Aug 18, 2026 | $6.64 | $7.03 | $6.58 | $6.93 | 4.78M |
The latest Smart Investors Daily articles mentioning BHC.
BHC research
Company profile and research snapshot.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 30, 2026 | TRUIST SECURITIES | Hold | — |
| Apr 29, 2026 | TD COWEN | Hold | — |
| Feb 20, 2026 | TD COWEN | Hold | — |
| Jan 27, 2026 | TD COWEN | Hold | — |
| Jan 26, 2026 | TD COWEN | Hold | — |
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering probiotherapeutical skincare products, announced the continued expansion of their strategic collaboration in Mexico and across additional EMEA markets following the 2025 launch in Poland.
Yahoo · Sep 8, 2026
Bausch Health, Canada Inc., a subsidiary of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), announces that SILIQ® (brodalumab injection) is now listed under Alberta's public drug plan for eligible patients who meet the applicable reimbursement criteria.
Yahoo · Sep 1, 2026
Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today announced the availability of Fraxel FTX® in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners (HCPs) beginning September 1, 2026.
Yahoo · Aug 27, 2026
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program. Since launching in 2013, the program has awarded 87 scholarships, totaling over $1 million, to students who have been treated for dermatologic conditions. This year, six inspiring students will each receive up to $10,000 to support their undergraduate or graduate studies.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BHC.
